Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Total Liabilities: 2014-2025

Historic Total Liabilities for AC Immune (ACIU) over the last 9 years, with Sep 2025 value amounting to $136.5 million.

  • AC Immune's Total Liabilities rose 3.64% to $136.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $397.6 million, marking a year-over-year increase of 31.07%. This contributed to the annual value of $135.4 million for FY2024, which is 441.85% up from last year.
  • Per AC Immune's latest filing, its Total Liabilities stood at $136.5 million for Q3 2025, which was up 97,730.27% from $139,488 recorded in Q2 2025.
  • AC Immune's 5-year Total Liabilities high stood at $23.9 billion for Q2 2021, and its period low was $139,488 during Q2 2025.
  • Moreover, its 3-year median value for Total Liabilities was $25.9 million (2024), whereas its average is $69.6 million.
  • As far as peak fluctuations go, AC Immune's Total Liabilities spiked by 102,794.84% in 2021, and later tumbled by 99.94% in 2022.
  • AC Immune's Total Liabilities (Quarterly) stood at $5.7 billion in 2021, then surged by 205.77% to $17.5 billion in 2022, then crashed by 99.86% to $25.0 million in 2023, then skyrocketed by 441.85% to $135.4 million in 2024, then climbed by 3.64% to $136.5 million in 2025.
  • Its Total Liabilities stands at $136.5 million for Q3 2025, versus $139,488 for Q2 2025 and $129.3 million for Q1 2025.